X4 Pharmaceuticals (XFOR) Consolidated Net Income (2017 - 2025)

X4 Pharmaceuticals (XFOR) has 9 years of Consolidated Net Income data on file, last reported at -$23.9 million in Q4 2025.

• For the quarter ending Q4 2025, Consolidated Net Income rose 39.92% year-over-year to -$23.9 million; the trailing twelve-month figure through Dec 2025 stood at -$79.2 million (down 111.48% YoY), and the FY2025 full-year result was -$79.2 million, down 111.48% from the prior year.
• Consolidated Net Income for Q4 2025 stood at -$23.9 million, up from -$29.8 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $90.8 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
• The 5-year median for Consolidated Net Income is -$22.9 million (2022), against an average of -$20.0 million.
• Peak annual rise in Consolidated Net Income reached 263.04% in 2024, while the deepest fall reached 1492.02% in 2024.
• A 5-year view of Consolidated Net Income shows it stood at -$30.2 million in 2021, then grew by 3.65% to -$29.1 million in 2022, then soared by 34.27% to -$19.1 million in 2023, then plunged by 108.16% to -$39.8 million in 2024, then soared by 39.92% to -$23.9 million in 2025.
• The last three Consolidated Net Income figures came in at -$23.9 million (Q4 2025), -$29.8 million (Q3 2025), and -$25.7 million (Q2 2025), per Business Quant data.

Peer Comparison